1. Academic Validation
  2. Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity

Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with In Vitro Growth Inhibitory and In Vivo Antitumor Activity

  • ACS Omega. 2022 Oct 3;7(41):36206-36226. doi: 10.1021/acsomega.2c03405.
Sümeyye Turanlı 1 Esra Nalbat 2 Deniz Lengerli 1 Kübra İbiş 1 Sezen Güntekin Ergün 2 Ece Akhan Güzelcan 2 Mesut Muyan 3 Rengul Cetin-Atalay 2 Burcu Çalışkan 1 Erden Banoglu 1
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University, Yenimahalle, Ankara 06560, Turkey.
  • 2 Cancer Systems Biology Laboratory, Graduate School of Informatics, Middle East Technical University, Ankara 06800, Turkey.
  • 3 Department of Biological Sciences, Middle East Technical University, Ankara 06800, Turkey.
Abstract

The vicinal diaryl heterocyclic framework has been widely used for the development of compounds with significant bioactivities. In this study, a series of diaryl heterocycles were designed and synthesized based on an in-house diaryl isoxazole derivative (9), and most of the newly synthesized derivatives demonstrated moderate to good antiproliferative activities against a panel of hepatocellular carcinoma and breast Cancer cells, exemplified with the diaryl isoxazole 11 and the diaryl pyrazole 85 with IC50 values in the range of 0.7-9.5 μM. Treatments with both 11 and 85 induced Apoptosis in these tumor cells, and they displayed antitumor activity in vivo in the Mahlavu hepatocellular carcinoma and the MDA-MB-231 breast Cancer xenograft models, indicating that these compounds could be considered as leads for further development of antitumor agents. Important structural features of this compound class for the antitumor activity have also been proposed, which warrant further exploration to guide the design of new and more potent diaryl heterocycles.

Figures
Products